Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • efanesoctocog alfa

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Sanofi reports improved patient outcomes from high-dose influenza vaccine

    Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

    Sha joined Sanofi in 2019 and takes up her new role with immediate effect

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links